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Abstract
Two exploratory studies were performed to deter-
mine the optimum therapeutic dose of Procox® for 
the removal of experimental infection with mature 
adult Toxocara (T.) cati and Ancylostoma (A.) tubae-
forme in kittens. Procox® is a new oral suspension 
containing a combination of the nematocidal and 
coccidiocidal active principles emodepside (0.1 %) 
and toltrazuril (2 %).
In the first study, 18 eight-weeks-old kittens were 
inoculated with 450 L3 larvae of T. cati. 56 days 
after infection, the kittens were allocated to three 
treatment groups and were treated with 0.5 mg 
emodepside/kg body weight (group 1), 0.25 mg 
emodepside/kg body weight (group 2) and 0.1 mg 
emodepside/kg body weight (group 3), respectively.
In the second study, 10 eight-weeks-old kittens 
were inoculated with 350 L3 larvae of A. tubae-
forme. Four weeks after infection, the kittens were 
allocated to two treatment groups and were treated 
with 0.1 mg emodepside/kg body weight (group 1) 
or 0.25 mg emodepside/kg body weight (group 2).
In both studies, all kittens received a  reference 
treatment with Drontal® (230 mg pyrantel 
embonate and 20 mg praziquantel per tablet) at the 
recommended dose of one tablet/4 kg body weight 
5 days after treatment with Procox®. Anthelmintic 
efficacy was calculated by reduction in worm num-
bers expelled with the faeces following treatment 
with Procox® as compared with faecal worm num-
bers after reference treatment with Drontal®, by 
thus avoiding necropsy of the animals.
In the T. cati study, emodepside was at 99.9 %, 
100 % and 96.5 % effective at a dosage of 0.5 mg, 
0.25 mg and 0.1 mg per kg body weight, respec-
tively. Against A. tubaeforme emodepside was at 
95.7 % and 100 % effective at a dosage of 0.1 mg 
and 0.25 mg per kg body weight. No adverse events 
were seen during either study.
It can be concluded that Procox® is  efficacious for 
the control of mature adult T. cati and A. tubaeforme 
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infections in cats at a single-dose rate of 0.25 mg 
emodepside/kg body weight.
Introduction
Infections with ascarids and hookworms are still 
the most common nematode infections in kittens 
and young adult cats worldwide as de monstrated in 
numerous current surveys (Beck and Pantchev 2008), 
with T. cati being the most common round worm in 
cats. Epe et al. (2004) detected T. cati (Zeder 1800) 
eggs in 3.9 % of feline  faecal samples in Ger many, 
while Barutzki and Schaper (2003) found ascarid 
eggs in 6.4 % of faecal samples. In Italy, Perrucci 
et al. (2001) found ascarid eggs in 28 % and hook-
worm eggs in 3 % of feline faecal samples. In Spain, 
 Gracenea et al. (2009) found T. cati eggs in 22 % and 
A. tubaeforme eggs in 4 % of feline faecal samples 
with distinct higher prevalences in kittens.
Cats can become infected with T. cati by one of 
the three routes: (1) direct ingestion of larvated 
eggs; (2) ingestion of a vertebrate host that har-
bours T. cati larvae in its tissues; or (3) by lacto-
genic transmission, in which larvae are passed in 
milk from a queen to her kittens (Sprent 1956). 
Accordingly, most infections in kittens are prob-
ably acquired lactogenically, whereas pre dation 
is the likely source for adult cats (Dubinsky et al. 
1995). Depending on the severity of infestation, 
clinical signs that can be seen in kittens are 
variable appetite, vomiting after feed, diarrhoea 
alternating with constipation, and developmental 
disturbances (Eckert 2000). Particularly in kittens, 
T. cati produce large numbers of eggs which are 
extremely resistant and long-lived in the environ-
ment. The kitten rather than the adult cat is thus 
responsible for increasing and spreading the danger 
of  parasitism. A cat’s living area which has become 
contaminated remains source of infection for a period 
of years.
Feline faeces also pose significant zoonotic threat 
because humans who ingest larvated T. cati eggs 
can develop visceral or ocular larva migrans 
(Overgaauw 1997). Tharaldsen (1982) found Toxo-
cara spp. eggs in 5 of 13 sandpits from Oslo munici-
pal nursery schools, which indicated a high faecal 
contamination from dogs and cats. Although epide-
miological studies carried out have concentrated on 
the canine T. canis as the main ethiological agent 
of the disease in man, also T. cati presents a high 
risk for man of acquiring toxocarosis (Dubinsky 
et al. 1995). 
Prevention and immediate therapy of patent infec-
tions are therefore key strategies for minimising 
the risk of zoonotic transmission with the kitten 
being the main target.
The hookworm A. tubaeforme can be detected in 
domestic cats worldwide. Prevalence rates from 
Europe and the US during recent years ranged 
between 0 – 75 % with highest rates of infection in 
feral or stray cats (Anderson 1992; Barutzki and 
Schaper 2003; Labarthe et al. 2004). Cats become 
infected by skin penetration or ingestion of infec-
tive third-stage (L3) larvae of A. tubaeforme with a 
prepatent period between 18 and 28 days depend-
ing on the infection route (Bowman et al. 2002). 
The adult parasites are present in the small intes-
tine, where they feed on host blood. While low to 
mo derate infections cause low-grade enteritis, 
heavy infections can lead to severe anaemia and 
possibly death (Hendrix 1995; Onwuliri et al. 1981).
Procox® oral suspension for dogs is a new oral 
suspension containing a combination of the nema-
tocidal and coccidiocidal active principles emodep-
side (0.1 %) and toltrazuril (2 %). It is approved 
for the treatment of puppies and young dogs with 
suspected or confirmed mixed infections caused by 
roundworms (T. canis, Uncinaria stenocephala, 
A. caninum) and Isospora (Isospora canis, Isospora 
ohioensis-complex). The nematocidal activity of 
emodepside has been established for dogs and cats 
(Altreuther et al. 2005, 2009; Schimmel et al. 2009; 
Reinemeyer et al. 2005) and is already approved 
for its veterinary use in combination with prazi-
quantel as Profender® spot-on for cats and Pro-
fender® tablets for dogs. So far, emodepside for the 
treatment of cats is formulated for dermal spot-on 
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administration only with proven efficacy against 
T. cati, Toxascaris leonina and A. tubaeforme.
The availability of the new oral combination  pro duct 
for puppies and the present use of emo depside as 
nematocidal active principle in Profender® spot-on 
for cats was a justification to test Procox® under 
experimental conditions in kittens. The purpose 
of the present studies was to titrate the dosage of 
emodepside in the combination product Procox® 
against the two most common feline nematodes 
T. cati and A. tubaeforme in kittens.
Materials and methods
Study design
Two exploratory studies were performed as ran-
domised, laboratory studies to evaluate the efficacy 
of Procox® oral suspension for dogs against experi-
mental T. cati and A. tubaeforme infections in 
kittens. Both studies were conducted as dose deter-
mination studies using a test procedure described 
by von Samson-Himmelstjerna et al. (2000). This 
test procedure uses experimentally infected ani-
mals which act as their own control. It provides 
reliable results at an early stage of screening of 
new drugs. Necropsy which is usually required for 
the controlled test and the critical test (Jacobs et al. 
1994) can be avoided by using a reference product 
with proven high anthelminitic efficacy. All ani-
mal procedures were approved by the responsible 
authorities and the animal welfare officer. Hus-
bandry of animals complied with the European 
Commission guidelines for the accommodation of 
animals used for experimental and other scientific 
purposes (June 18 2007/526/EC). The design of 
both studies is summarised in Tab. 1.
Study animals
In both studies, healthy purpose-bred kittens were 
used that had not been treated previously with 
anthelmintic or anticoccidial drugs. All kittens 
were acclimatised to the study facilities for at least 
seven days before the experimental infection. They 
were identified by ear tattoo number. Kittens were 
eight weeks of age at the day of experimental infec-
tion in both studies. The body weight (b.w.) ranged 
between 1.2 and 2.2 kg. Kittens were housed in 
groups during the prepatent period and were then 
transferred to single housing during the patent 
period to facilitate individual faecal sampling. 
Kittens were fed once daily a commercial dry cat 
food and had ad libitum access to water. General 
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determined by a veterinary examination before the 
start of the study.
Clinical observations
The general health of all kittens was assessed 
once before the experimental infection, once before 
treatment and once daily after treatment. Kittens 
were evaluated for general attitude and behaviour, 
and faecal consistency was assessed. Following 
treatment, cats were also observed every hour for 
6 hours after dosing for any potential adverse reac-
tions to the test product.
Infection
In both studies, kittens were experimentally infected. 
In study A, the T. cati infection was induced by an 
oral administration of approximately 450 L3 larvae 
eight weeks before the start of the study. In study 
B, the A. tubaeforme infection was induced by an 
oral administration of approximately 350 L3 larvae 
four weeks before the start of the study. The strains 
had been isolated from naturally infected cats from 
a northern region in Germany and thereafter had 
been passaged in cats several times and in this way 
kept in culture at the study facility.
Treatment
In both studies, kittens were ranked according to 
their faecal egg counts from day 0 and were ran-
domly allocated to treatment groups. Kittens were 
weighed prior to treatment, and body weights were 
used to determine individual doses of the Procox® 
oral suspension to be administered once at day 0.
In study A (T. cati), three study groups with 6 kit-
tens each were treated at day 56 (8 weeks) post 
infection. In study B (A. tubaeforme), two study 
groups with 5 kittens each were treated at day 
26 post infection. Applied doses of emodepside and 
toltrazuril are given in Tab. 2.
As a reference treatment, all kittens were treated at 
day 5 after Procox® treatment with the anthelmintic 
product Drontal® tablets for cats containing 20 mg 
praziquantel and 230 mg pyrantel embonate per tab-
let. Each kitten received the re commended dosage 
of 5 mg praziquantel + 57.5 mg pyrantel embonate 
per kg body weight as single oral application.
Parasitological techniques
A faecal egg count (FEC) using a modified McMas-
ter method was performed for each kitten before 
treatment with Procox® on day 0 to determine 
whether a patent infection was established. Total 
24-hour faeces were collected daily from each kit-
ten for 5 days after treatment with Procox® in both 
the T. cati study (study A) and the A. tubaeforme 
study (study B) for the determination of adult 
worm numbers excreted with faeces. Faecal worm 
counts were continued for 3 days after treatment 
with Drontal®. Faeces were processed by soaking 
the material over night. The total amount of faeces 
was washed gently over a 75 µm sieve to recover 
all nematodes eliminated from the gastrointestinal 
Tab. 2   Procox® oral suspension doses and Drontal® pyrantel embonate/praziquantel doses used against mature T. cati 
(study A) and mature A. tubaeforme (study B) in kittens
Study
Number of kittens 
per group
Emodepside (E) +  
Toltrazuril (T) 
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tract by treatment. All adult T. cati or A. tubae-
forme found were counted under the microscope. 
Efficacy calculation
Efficacy of the different emodepside doses was cal-
culated by comparing the total faecal worm counts 
of each kitten from day 0 to day 8 and the worm 
counts from day 0 to day 5 according to von Sam-
son-Himmelstjerna et al. (2000).
The percentage reduction of worm numbers was 








The presence of a patent infection of T. cati and 
A. tubaeforme was demonstrated by positive egg 
counts in faecal samples from all kittens on day 
0 before treatment with Procox®.
Study A (T. cati)
All three emodepside doses were highly effective 
against mature T. cati infections (Tab. 3). Full 
anthelmintic efficacy was obtained in study group 
1 (99.9 %) and 2 (100 %) with 0.5 and 0.25 mg 
emodepside per kg b.w., respectively. Worm counts 
in group 1 and 2 were negative starting on day 
3 post treatment. After reference treatment with 
Drontal®, no further worms were shed by any of the 
kittens in group 2 and one worm was shed by one 
kitten in group 1. In group 3, 96.5 % worm count 
reduction was achieved at an emodepside dose of 
0.1 mg/kg b.w. with five out of six kittens shed-
ding no further worms and one kitten shedding 
13 worms after the reference treatment.
Study B (A. tubaeforme)
Procox® was 95.7 % effective against mature 
A. tubaeforme infections at an emodepside dose of 
0.1 mg per kg b.w. in group 1. Four out of five kit-
tens did not shed any further worm after reference 
treatment, whereas one kitten shed 8 worms.
In group 2, 100 % efficacy was achieved at an 
emodepside dose of 0.25 mg per kg b.w. (Tab. 3). 
At day 3 post treatment, worm counts were nega-
tive. No worms were shed after reference treatment 
with Drontal®. 
As demonstrated in both studies by an easy and 
uncomplicated uptake, the Procox® oral suspension 
was highly palatable. In all dose groups, no adverse 
reactions due to Procox® treatment were observed 
during the post treatment interval.
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E: 0.5 + T: 10.0 6 97/164/15/140/100/196 97/165/15/140/100/196 0/1/0/0/0/0 99.9
E: 0.25 + T: 5.0 6 63/54/46/20/26/71 63/54/46/20/26/71 0/0/0/0/0/0 100
E : 0.1 + T: 2.0 6 60/19/45/67/7/73 60/19/45/80/7/73 0/0/0/13/0/0 96.5
B
E: 0.1 + T: 2.0 5 19/19/10/29/56 19/19/10/37/56 0/0/0/8/0 95.7




Both studies were designed as preliminary dose 
finding studies to determine the optimum thera-
peutic dose of Procox® for the removal of adult 
mature T. cati and A. tubaeforme in kittens. To 
avoid necropsy, which is usually required for 
critical and controlled tests in later stage of drug 
develop ment, in this study a method described by 
von Samson-Himmelstjerna et al. (2000) was used. 
The test procedure uses experimentally infected 
animals which act as their own control and gives 
reliable results at an early stage of screening.
In both studies, experimental infections were induced 
with L3 larvae, and the presence of a patent infection 
of T. cati and A. tubaeforme was demonstrated by 
positive egg counts in faecal samples from all kittens 
on day 0 before treatment with the test product.
In the T. cati study, a single treatment with the 
emodepside/toltrazuril combination produced a 
worm reduction of 99.9 %, 100 % and 96.5 % using 
0.5 mg, 0.25 mg and 0.1 mg emodepside per kg b.w., 
respectively. In the A. tubaeforme study, a single 
treatment with the emodepside/toltrazuril combi-
nation produced a worm reduction of 100 % and 
95.7 % using 0.25 mg and 0.1 mg emodepside per 
kg b.w., respectively. 
It can be concluded that in both experimentally 
induced infections, Procox® was highly efficacious in 
the control of mature adult T. cati and A.  tubaeforme 
at a single oral dose rate corresponding to 0.25 mg 
emodepside per kg b.w. 
The Procox® application was well tolerated and 
no adverse events were noted at any dosages 
of emodepside/tolrazuril oral suspension in the 
 studies reported here.
Oral administration of the suspension to kittens 
was easy because palatability was high. This sup-
ports for a high degree of owner and breeder com-
pliance within a nematode control programme. 
Within the context that certain feline nematodes 
still occur with high prevalences, the effective con-
trol of feline ascarids and hookworms is important 
because of their potential pathogenicity in both 
cats and humans.
The efficacy, safety and high palatability of the 
Procox® oral suspension offers a suitable treat-
ment option for kittens affected by ascarid and 
hookworm infections.
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